Cargando…
(131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients
Incomplete response to therapy may compromise the outcome of children with advanced neuroblastoma. In an attempt to improve tumour response we incorporated (131)I-metaiodobenzylguanidine ((131)I-MIBG) in the treatment regimens of selected stage 3 and stage 4 patients. Between 1986 and 1997, 43 neuro...
Autores principales: | Garaventa, A, Bellagamba, O, Piccolo, M S Lo, Milanaccio, C, Lanino, E, Bertolazzi, L, Villavecchia, G P, Cabria, M, Scopinaro, G, Claudiani, F, Bernardi, B De |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362971/ https://www.ncbi.nlm.nih.gov/pubmed/10604736 http://dx.doi.org/10.1038/sj.bjc.6694223 |
Ejemplares similares
-
The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013) -
Toxicity of upfront (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis
por: Bleeker, Gitta, et al.
Publicado: (2013) -
Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
por: George, Sally L., et al.
Publicado: (2016) -
MON-202 Germline SDHB Exon 1 Deletion Is Associated with Absence of (131)I-metaiodobenzylguanidine (MIBG) Uptake in Malignant Paragangliomas
por: Petenuci, Janaina, et al.
Publicado: (2020) -
I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma
por: Sato, Yuya, et al.
Publicado: (2012)